Engineering active siRNA therapeutics

نویسندگان

چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

What is the Future of SiRNA Therapeutics?

RNA interference (RNAi) – gene silencing by double-stranded RNA, is a Nobel Prize winning discovery by Fire and Mellow [1]. Since RNAi was found to occur in mammalian cells, it has been intensively investigated as a new therapeutic strategy. RNAi can be triggered by the introduction of synthetic sequence-specific small interfering RNA (siRNA), which is able to target and cleave complementary me...

متن کامل

Antibody Engineering and Therapeutics

note: The views expressed herein are those of the authors and do not necessarily reflect the views of their respective employers. Speakers who wrote a summary of their own presentation are listed in the header for the relevant session. The majority of the other summaries in this report were based on PDFs of the presentations provided by speakers or on post-meeting input from the speakers. The a...

متن کامل

Engineering Ribonuclease - Based Cancer Therapeutics

............................................................................................................................ i Acknowledgements ............................................................................................................ iv Table of

متن کامل

Antibody engineering and therapeutics conference

Half-day pre-conference workshops on three-dimensional (3D) structure antibody modeling and on identifying clonal lineages from next-generation data sets of expressed VH gene sequences will be held on Sunday December 8, 2013. The modeling workshop will be moderated by Juan Carlos Almagro (Pfizer, Inc and Gary L Gilliland (Janssen R&D, Inc. With the success of antibody-based therapeutics, protei...

متن کامل

Design of siRNA Therapeutics from the Molecular Scale

While protein-based therapeutics is well-established in the market, development of nucleic acid therapeutics has lagged. Short interfering RNAs (siRNAs) represent an exciting new direction for the pharmaceutical industry. These small, chemically synthesized RNAs can knock down the expression of target genes through the use of a native eukaryotic pathway called RNA interference (RNAi). Though si...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: FEBS Journal

سال: 2010

ISSN: 1742-464X

DOI: 10.1111/j.1742-4658.2010.07902.x